DX-8951f in Treating Patients With Metastatic Stomach Cancer

DISEASE CHARACTERISTICS:

• Histologically confirmed gastric or gastroesophageal adenocarcinoma
• Lymph node involvement and/or distant metastasis
• No squamous cell carcinoma, small cell carcinoma, lymphoma, or leiomyosarcoma of the stomach
• Measurable disease with indicator lesions outside the field of prior radiotherapy
• At least 20 mm by conventional scan OR
• At least 10 mm by spiral CT scan
• Nonmeasurable lesions include the following:
• Primary tumor
• Bone lesions
• Leptomeningeal disease
• Ascites
• Pleural/pericardial effusion
• Inflammatory breast disease
• Lymphangitis cutis/pulmonitis
• Cystic lesions
• Abdominal masses not confirmed and followed by imaging techniques
• No prior treatment for locally advanced or metastatic disease
• Prior adjuvant treatment allowed if disease recurrence noted at least 6 months after completion of adjuvant treatment
• No known brain metastases

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 12 weeks

Hematopoietic:

• Absolute neutrophil count at least 1,500/mm3
• Platelet count at least 100,000/mm3
• Hemoglobin at least 9.0 g/dL

Hepatic:

• Bilirubin no greater than 2.0 mg/dL
• AST or ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present)
• Albumin at least 2.8 g/dL
• PT or INR no greater than 1.5 times ULN (coumadin independent)

Renal:

• Creatinine no greater than 1.5 mg/dL

Cardiovascular:

• No active congestive heart failure
• No uncontrolled angina
• No myocardial infarction within the past 6 months

Other:

• No concurrent serious infection
• No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
• No overt psychosis, mental disability, or incompetence that would preclude informed consent
• No other life-threatening illness
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

Biologic therapy:

• No concurrent anti-cancer biologic therapy
• No concurrent prophylactic colony stimulating factors during first course of therapy

Chemotherapy:

• Recovered from prior adjuvant chemotherapy
• No other concurrent anti-cancer chemotherapy
• No other concurrent anti-cancer cytotoxic therapy

Endocrine therapy:

• Concurrent megestrol for appetite stimulation allowed

Radiotherapy:

• At least 4 weeks since prior radiotherapy and recovered
• No prior wide-field radiotherapy to more than 25% of bone marrow
• No concurrent anti-cancer radiotherapy

Surgery:

• At least 4 weeks since prior major surgery and recovered
• No concurrent anti-cancer surgery

Other:

• No other investigational drugs (including analgesics or antiemetics) for at least 4 weeks prior to, during, and for 4 weeks after study